Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.

A Complex Case: Combined Lactic Acidosis and Ketoacidosis in a Diabetic Patient

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have become a cornerstone of diabetes management, offering significant benefits for patients with type 2 diabetes (T2DM), heart failure, and chronic kidney disease. However, like any medication, SGLT2i can have rare side effects, including euglycemic diabetic ketoacidosis (EDKA) and metformin-associated lactic acidosis (MALA). This case report describes a patient with T2DM and severe heart failure who developed a rare combination of EDKA and MALA.

Navigating the Complexities of Diabetes Management

The case report highlights the potential for serious complications when combining metformin and SGLT2i therapy, especially in patients with underlying health conditions. It emphasizes the importance of vigilant monitoring for signs of EDKA and MALA in patients receiving these medications, particularly those with risk factors such as renal impairment or heart failure.

Balancing the Benefits and Risks of Diabetes Medications

The case report underscores the need for a nuanced approach to diabetes management, carefully weighing the benefits and risks of different medications. It highlights the importance of personalized care, tailored to individual patient needs and risk factors. Close collaboration between patients and healthcare professionals is crucial for optimal diabetes management and minimizing the risk of complications.

Dr.Camel's Conclusion

Navigating the complex landscape of diabetes management requires a careful balance between benefits and risks. This case report serves as a reminder that even seemingly safe medications can have unexpected interactions, especially in patients with multiple health conditions. It emphasizes the importance of ongoing research, vigilant monitoring, and personalized care for individuals living with diabetes.